Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus

Lupus

Volumn 19, Issue 2, 2010, Pages 146-157

  Tew, G W ^a   Rabbee, N ^a   Wolslegel, K ^a   Hsieh, H J ^a   Monroe, J G ^a   Behrens, T W ^a   Brunetta, P G ^a   Keir, M E ^a  

^a GENENTECH INC   (United States)

Author keywords

Anti DNA antibodies; Hematologic changes; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; B CELL ACTIVATING FACTOR; CARDIOLIPIN ANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; INTERFERON; LA ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; RO ANTIBODY;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL SELECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BIOLOGICAL MARKERS; COMPLEMENT SYSTEM PROTEINS; DNA; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA-BINDING PROTEINS;

EID: 76049097862     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309350752     Document Type: Article

References (21)

1. Arce E., Jackson DG, Gill MA, Bennett LB, Banchereau J., Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001 ; 167: 2361-2369.
2. Odendahl M., Jacobi A., Hansen A., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000 ; 165: 5970-5979.
3. Wei C., Anolik J., Cappione A., et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007 ; 178: 6624-6633.
4. Looney RJ, Anolik JH, Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 ; 50: 2580-2589.
5. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005 ; 14: 210-214.
6. Looney RJ, Anolik J., Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 2005 ; 8: 193-205.
7. Hay EM, Bacon PA, Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993 ; 86: 447-458.
8. Isenberg DA, Gordon C. From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 2000 ; 9: 651-654.
9. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately-to-severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER Arthritis Rheum (in press).
10. Jonsdottir T., Gunnarsson I., Risselada A., Henriksson EW, Klareskog L., van Vollenhoven RF Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008 ; 67: 330-334.
11. Vallerskog T., Gunnarsson I., Widhe M., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007 ; 122: 62-74.
12. Shlomchik MJ, Craft JE, Mamula MJ From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001 ; 1: 147-153.
13. Ioannou Y., Lambrianides A., Cambridge G., Leandro MJ, Edwards JC, Isenberg DA B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008 ; 67: 425-426.
14. Vallerskog T., Heimburger M., Gunnarsson I., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006 ; 8: R167.
15. Lesley R., Xu Y., Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004 ; 20: 441-453.
16. Baechler EC, Batliwalla FM, Karypis G., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003 ; 100: 2610-2615.
17. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008 ; 141: 149-169.
18. Albert D., Dunham J., Khan S., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008 ; 67: 1724-1731.
19. Jacobi AM, Reiter K., Mackay M., et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008 ; 58: 1762-1773.
20. Horak P., Scudla V., Hermanovo Z., et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001 ; 20: 337-344.
21. Ng KP, Cambridge G., Leandro MJ, Edwards JC, Ehrenstein M., Isenberg DA B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007 ; 66: 1259-1262.